AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical (NASDAQ: RCEL) secured a 10-year agreement with BARDA under Project BioShield, valued at up to $25.5 million to strengthen U.S. burn mass casualty preparedness.
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) secured a 10-year agreement with BARDA under Project BioShield, valued at up to $25.5 million to strengthen U.S. burn mass casualty preparedness. The contract provides BARDA access to 3,000 RECELL units over the term, plus procurement options and readiness support.
Approximately $3.97 million is expected as access-maintenance and readiness fee revenue over 10 years; remaining value reflects optional procurements BARDA may exercise.
Positive
- 10-year BARDA agreement valued up to $25.5M
- Guaranteed access-maintenance revenue of $3.97M over 10 years
- BARDA access to 3,000 RECELL units for rapid deployment
- Strengthens decade-long public health partnership with BARDA
Negative
- Majority of $25.5M is contingent on BARDA exercising procurement options
- Only $3.97M is expected guaranteed revenue across the 10-year term
Details
News Market Reaction – RCEL
On Apr 9, the first trading day after this news, RCEL closed 10.73% above the previous close.
Data tracked by StockTitan Argus for the Apr 9 session.
Key Figures
- BARDA agreement value
- $25.5M
- Total potential value over 10-year contract under Project BioShield
- Access-maintenance revenue
- $3.97M
- Expected over 10 years from annual access-maintenance and readiness support fees
- Contract term
- 10 years
- Duration of BARDA agreement for burn mass casualty preparedness
- RECELL units available
- 3,000 units
- Units BARDA can access at any time over the contract
- Contract number
- 75A50125C00012
- BARDA contract identifier cited for federal funding
Historical Context
-
Announcement of management presenting at TD Cowen health care conference.
-
Planned investor webinar to review Q4 and full-year 2025 results.
-
Q4 and FY 2025 results with revenue growth and high gross margin plus 2026 guidance.
-
Boswick Symposium data on RECELL, PermeaDerm, Cohealyx integration and outcome benefits.
-
Pre-J.P. Morgan update mixing revenue growth with tighter credit facility covenants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biomedical advanced research and development authority regulatory
project bioshield regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract
VALENCIA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a therapeutic acute wound care company, today announced it has entered into a 10-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The agreement, awarded under Project BioShield and valued at up to
“Through this agreement, AVITA is supporting national preparedness by helping expand access to RECELL during mass casualty incidents,” said Cary Vance, Interim Chief Executive Officer of AVITA Medical. “We value our ongoing collaboration with BARDA to strengthen the nation’s ability to respond when it matters most.”
Under the agreement, AVITA Medical will:
- Maintain an inventory of RECELL products available for immediate deployment upon notice from BARDA and support surge procurement of additional product, ensuring scalable emergency response capacity.
- Provide logistics, quality assurance, and deployment readiness to meet BARDA’s mission for preparedness.
In the event of a BMCI, the RECELL products will be deployed to designated centers with trained staff, ensuring rapid and effective use.
The agreement carries a total potential value of up to
This partnership underscores AVITA Medical’s commitment to delivering value to the U.S. government through discounted pricing, proven manufacturing and logistics capabilities, and robust compliance. It builds on a decade-long partnership with BARDA to advance burn care innovation and strengthen public health readiness.
This project is funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50125C00012.
About AVITA Medical, Inc.
AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL, approved by the FDA for the treatment of thermal burns and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and manufactures and holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications including thermal burns and trauma wounds. RECELL and RECELL GO® have received the CE mark in Europe; and RECELL is TGA-registered in Australia and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “could,” “expect,” “may,” “potential,” “valued,” “will,” “would,” and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: industry market conditions; failure to obtain and/or maintain regulatory approvals and comply with applicable regulations; supply chain disruptions that could affect our ability to manufacture our products; market reaction to growth or product initiatives; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. Any forward-looking statements made herein are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On SkinTM Cells are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.